EZH2 and ovarian carcinoma: Figure 4 presents the EZH2 expression in cystadenoma and ovarian carcinoma with and without metastasis. CAF in metastatic ovarian carcinoma had the highest EZH2 expression of the groups assessed (χ2 = 26.945, P = 0.000) (Table 4). There were statistically significant differences between group I and group II (Z = −3.203, P = 0.001), group II and group III (Z = −4.814, P = 0.000), and group II and group IV (Z = −3.785, P = 0.000).